<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent reviews have questioned whether the <z:chebi fb="19" ids="28790">serotonin</z:chebi>-<z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> reuptake inhibitor (SNRI) desvenlafaxine succinate offers any practical clinical advantages over existing SNRIs </plain></SENT>
<SENT sid="1" pm="."><plain>The following case is one instance where it appears that this SNRI offers unique safety and benefit </plain></SENT>
<SENT sid="2" pm="."><plain>Presented is a case report of a patient with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, longstanding <z:e sem="disease" ids="C0031572" disease_type="Mental or Behavioral Dysfunction" abbrv="">social phobia</z:e>, and more recent <z:e sem="disease" ids="C0868892,C0868894,C0011581,C0012706,C0868893" disease_type="Mental or Behavioral Dysfunction" abbrv="">depressive disorder</z:e> not otherwise specified, who was found to have elevated liver transaminases when prescribed both <z:chebi fb="0" ids="36796">duloxetine</z:chebi> and <z:chebi fb="0" ids="9943">venlafaxine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The patient subsequently responded to desvenlafaxine but without <z:hpo ids='HP_0001392'>liver abnormalities</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In this patient with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's Syndrome</z:e>, desvenlafaxine's lack of metabolism through the <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> (<z:chebi fb="0" ids="38559">CYP</z:chebi>) 2D6 pathway may explain the avoidance of these abnormalities and thus suggests a possible therapeutic role for this SNRI in similarly susceptible patients </plain></SENT>
</text></document>